Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA

Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA
Trade Name
Orphan Indication Acute myeloid leukemia
USA Market Approval USA
USA Designation Date 2005-04-15 00:00:00
Sponsor Lorus Therapeutics, Inc.;2 Meridan Road;M9W 4Z7
Related Access Program
Children’s Hospital Los Angeles – Acute myeloid leukemia Jazz Pharmaceuticals – Secondary AML Celator Pharmaceuticals – Secondary AML University of California, San Francisco – Acute myeloid leukemia Emory University – Acute myeloid leukemia